

Hong Kong Exchanges and Clearing Limited and The Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司

NORTHEAST TIGER PHARMACEUTICAL CO., LTD

(A joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 08197)

Clarification Announcement

Reference is made to the announcement of Northeast Tiger Pharmaceutical Co., Ltd (the “Company”) dated 31 March 2017 in relation to date of board meeting (the “Announcement”). Save as otherwise provided, terms used herein shall have the same meanings as used in the Announcement.

Due to typographical error, the Board wishes to clarify that the first paragraph in the announcement shall be “The board of directors (the “Board”) of Northeast Tiger Pharmaceutical Co., Ltd (the “Company”) announces that a meeting of the Board will be held on 8 May 2017 at 4:00 p.m., for the purpose of, among other matters, approving for publication the announcement of the unaudited first quarterly results of the Company for the three months ended 31 March 2017 and considering the payment of an interim dividend (if any).” instead of “The board of directors (the “Board”) of Northeast Tiger Pharmaceutical Co., Ltd (the “Company”) announces that a meeting of the Board will be held on 8 May 2017 at 4:00 p.m., for the purpose of, among other matters, approving for publication the announcement of the unaudited first quarterly results of the Company for the three months ended 31 March 2017 and considering the payment of a final dividend (if any).”.

Save as disclosed above, the Board confirms that all information in the Announcement remains unchanged.

By Order of the Board
Chairman
Wang Shaoyan

Beijing, the PRC
3 April 2017

As at the date of this announcement, the Company’s executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company’s non-executive directors are Guo Aiqun and Cao Yang and the Company’s independent non-executive directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam..

This announcement, for which the directors (the “Directors”) of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their

knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at <http://www.hkgem.com> for at least 7 days from the day of its posting.